Journal of Advances in Clinical Nursing

The therapeutic effect of tumor immunotherapy is remarkable, but the related complications cause adverse effects on recovery and lead to poor prognosis. At present, there are no nursing guidelines on immune-associated colitis. Therefore, this study summarized the nursing experience of a patient with advanced lung cancer who developed immune-associated colitis after 4 cycles of treatment with sindellizumab combined with gemcitabine, and achieved early identification, early treatment and early nursing at the early stage, so as to control the disease and improve the prognosis, hoping to provide reference for the follow-up nursing of similar cases. The key points of care are flushable excreta management kit, skin management with low negative pressure attraction, phased nutrition intervention based on immune nutrients, and improved enema retention of Chinese medicine enema care. After 13 days, the patients symptoms improved and he was discharged successfully. After a follow-up visit one month later, no abnormality was found in the colonoscopy and antitumor therapy was continued.

PD-1 inhibitor; Sindilimab; Immune-associated colitis; Lung cancer; Nurse